Please note that this product was withdrawn from the Union Register of orphan medicinal products in January 2021 on request of the sponsor.
On 27 July 2010, orphan designation (EU/3/10/754) was granted by the European Commission to Bioarctic Neuroscience AB, Sweden, for heparin-activated recombinant human fibroblast growth factor 1 (on a biodegradable device made from alpha-calcium sulphate hemihydrate) for the treatment of traumatic spinal cord injury.
In September 2016, Bioarctic Neuroscience AB changed name to BioArctic AB.
EU/3/10/754: Public summary of opinion on orphan designation: Heparin-activated recombinant human fibroblast growth factor 1 (on a biodegradable device ade from alpha-calcium sulphate hemihydrate) for the treatment of tr... (PDF/232.66 KB)
First published: 05/08/2010
Last updated: 03/02/2021
Heparin-activated recombinant human fibroblast growth factor 1 (on a biodegradable device made from alpha-calcium sulfate hemihydrate)
|Disease / condition||
Treatment of traumatic spinal cord injury
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.